SCHEMBL3302833

SCHEMBL3302833

CCOC(=O)Cc1c(C)c(Sc2ccc(C(=O)N3CCCC3)cc2)n2cc(F)ccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.41
HPGD P15428 7/20 0.39
KDM4E B2RXH2 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CNR2 P34972 1/20 0.39
HTT P42858 2/20 0.39
ADORA2A P29274 2/20 0.39
ALDH1A1 P00352 5/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
MAPT P10636 2/20 0.38
RAB9A P51151 1/20 0.38
HSD17B10 Q99714 1/20 0.36
MAPK1 P28482 1/20 0.36
STAT3 P40763 1/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
POLB P06746 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3332659 0.89 PTGDR2 (0.52) PTGDR2HPGDKDM4EL3MBTL1HTT
SCHEMBL3304453 0.84 PTGDR2 (0.46) PTGDR2HPGDL3MBTL1ALDH1A1MEN1
SCHEMBL3569716 0.83 PTGDR2 (0.45) PTGDR2KDM4EL3MBTL1ALDH1A1MEN1
SCHEMBL2774269 0.80 PTGDR2 (0.51) PTGDR2KDM4EHTTALDH1A1MEN1
SCHEMBL3302504 0.79 PTGDR2 (0.41) PTGDR2KDM4EL3MBTL1MEN1KMT2A
SCHEMBL2771887 0.79 PTGDR2 (0.47) PTGDR2HPGDL3MBTL1ALDH1A1MEN1
SCHEMBL3302540 0.79 PTGDR2 (0.42) PTGDR2HPGDKDM4EL3MBTL1ALDH1A1
SCHEMBL2771246 0.79 PTGDR2 (0.46) PTGDR2HPGDKDM4EL3MBTL1HTT
SCHEMBL3579992 0.79 PTGDR2 (0.48) PTGDR2KDM4EALDH1A1MEN1KMT2A
SCHEMBL3303652 0.77 PTGDR2 (0.40) PTGDR2HPGDKDM4EL3MBTL1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093751-A1 Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor ARGENTA DISCOVERY LIMITED (GB) 2010-04-15 US disclosed
EP-2121686-A1 INDOLIZINEACETIC ACIDS AND THEIR THERAPEUTIC USE AS LIGANDS OF THE CRTH2 RECEPTOR Argenta Discovery Limited (GB) 2009-11-25 EP disclosed
WO-2008078069-A1 INDOLIZINEACETIC ACIDS AND THEIR THERAPEUTIC USE AS LIGANDS OF THE CRTH2 RECEPTOR ARGENTA DISCOVERY LIMITED (GB) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093751-A1 Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor HRH2, HRH4, HRH1 PTGDR2 168/4885HPGD 1077/4885KDM4E 4791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.